138 related articles for article (PubMed ID: 35925914)
1. Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial.
Audemard-Verger A; Le Gouge A; Pestre V; Courjon J; Langlois V; Vareil MO; Devaux M; Bienvenu B; Leroy V; Goulabchand R; Colombain L; Bigot A; Guimard T; Douadi Y; Urbanski G; Faucher JF; Maulin L; Lioger B; Talarmin JP; Groh M; Emmerich J; Deriaz S; Ferreira-Maldent N; Cook AR; Lengellé C; Bourgoin H; Mekinian A; Aouba A; Maillot F; Caille A
PLoS One; 2022; 17(8):e0269065. PubMed ID: 35925914
[TBL] [Abstract][Full Text] [Related]
2. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.
CORIMUNO-19 Collaborative group
Lancet Respir Med; 2021 Mar; 9(3):295-304. PubMed ID: 33493450
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial.
Fanlo P; Gracia-Tello BDC; Fonseca Aizpuru E; Álvarez-Troncoso J; Gonzalez A; Prieto-González S; Freire M; Argibay AB; Pallarés L; Todolí JA; Pérez M; Buján-Rivas S; Ibáñez B;
JAMA Netw Open; 2023 Apr; 6(4):e237243. PubMed ID: 37027155
[TBL] [Abstract][Full Text] [Related]
4. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
6. An open label trial of anakinra to prevent respiratory failure in COVID-19.
Kyriazopoulou E; Panagopoulos P; Metallidis S; Dalekos GN; Poulakou G; Gatselis N; Karakike E; Saridaki M; Loli G; Stefos A; Prasianaki D; Georgiadou S; Tsachouridou O; Petrakis V; Tsiakos K; Kosmidou M; Lygoura V; Dareioti M; Milionis H; Papanikolaou IC; Akinosoglou K; Myrodia DM; Gravvani A; Stamou A; Gkavogianni T; Katrini K; Marantos T; Trontzas IP; Syrigos K; Chatzis L; Chatzis S; Vechlidis N; Avgoustou C; Chalvatzis S; Kyprianou M; van der Meer JW; Eugen-Olsen J; Netea MG; Giamarellos-Bourboulis EJ
Elife; 2021 Mar; 10():. PubMed ID: 33682678
[TBL] [Abstract][Full Text] [Related]
7. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A
J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354
[TBL] [Abstract][Full Text] [Related]
8. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
9. Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial.
Sundén-Cullberg J; Chen P; Häbel H; Skorup P; Janols H; Rasmuson J; Niward K; Östholm Balkhed Å; Chatzidionysiou K; Asgeirsson H; Blennow O; Parke Å; Svensson AK; Muvva JR; Ljunggren HG; ; Horne AC; Ådén U; Henter JI; Sönnerborg A; Vesterbacka J; Nowak P; Lampa J
PLoS One; 2023; 18(12):e0295838. PubMed ID: 38157348
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
Ely EW; Ramanan AV; Kartman CE; de Bono S; Liao R; Piruzeli MLB; Goldman JD; Saraiva JFK; Chakladar S; Marconi VC;
Lancet Respir Med; 2022 Apr; 10(4):327-336. PubMed ID: 35123660
[TBL] [Abstract][Full Text] [Related]
11. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series.
Navarro-Millán I; Sattui SE; Lakhanpal A; Zisa D; Siegel CH; Crow MK
Arthritis Rheumatol; 2020 Dec; 72(12):1990-1997. PubMed ID: 32602262
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia.
Pontali E; Volpi S; Signori A; Antonucci G; Castellaneta M; Buzzi D; Montale A; Bustaffa M; Angelelli A; Caorsi R; Giambruno E; Bobbio N; Feasi M; Gueli I; Tricerri F; Calautti F; Castagnola E; Moscatelli A; Rollandi GA; Ravelli A; Cassola G; Sormani MP; Gattorno M
J Allergy Clin Immunol; 2021 Apr; 147(4):1217-1225. PubMed ID: 33556464
[TBL] [Abstract][Full Text] [Related]
13. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study.
Balkhair A; Al-Zakwani I; Al Busaidi M; Al-Khirbash A; Al Mubaihsi S; BaTaher H; Al Aghbari J; Al Busaidi I; Al Kindi M; Baawain S; Al Alawi A; Al Lawati A; Al Rawahi B; Al-Baimani K; Al Zidi K; Elfatih N; Dawud B; John B; Rehman F; Yousif F; Al Khadouri G; Saber I; Lal J; Gargouri M; Al-Ward M; AbuDraz N; Al Ruqeishi S; Kumar S; Abdelmottaleb W; Al-Naamani Z; Bin Nazar Z; Balkhair O
Int J Infect Dis; 2021 Feb; 103():288-296. PubMed ID: 33217576
[TBL] [Abstract][Full Text] [Related]
14. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
15. Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial.
Dushianthan A; Clark H; Madsen J; Mogg R; Matthews L; Berry L; de la Serna JB; Batchelor J; Brealey D; Hussell T; Porter J; Djukanovic R; Feelisch M; Postle A; Grocott MPW
Trials; 2020 Dec; 21(1):1014. PubMed ID: 33302976
[TBL] [Abstract][Full Text] [Related]
16. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm.
Jackson LE; Khullar N; Beukelman T; Chapleau C; Kamath A; Cron RQ; Chatham WW
Viruses; 2023 Sep; 15(10):. PubMed ID: 37896812
[TBL] [Abstract][Full Text] [Related]
18. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a Systematic review and meta-analysis.
Barkas F; Filippas-Ntekouan S; Kosmidou M; Liberopoulos E; Liontos A; Milionis H
Rheumatology (Oxford); 2021 Dec; 60(12):5527-5537. PubMed ID: 33999135
[TBL] [Abstract][Full Text] [Related]
19. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
20. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.
Pasin L; Cavalli G; Navalesi P; Sella N; Landoni G; Yavorovskiy AG; Likhvantsev VV; Zangrillo A; Dagna L; Monti G
Eur J Intern Med; 2021 Apr; 86():34-40. PubMed ID: 33581979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]